Leap

Leap Uses, Dosage, Side Effects, Food Interaction and all others data.

Leap was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.

Leap, a selective cyclooxygenase-2 (COX-2) inhibitor, is classified as a nonsteroidal anti-inflammatory drug (NSAID). Leap is used for its anti-inflammatory, analgesic, and antipyretic activities in the management of osteoarthritis (OA) and for the treatment of dysmenorrhea or acute pain. Unlike celecoxib, valdecoxib lacks a sulfonamide chain and does not require CYP450 enzymes for metabolism.

Leap
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Leap
Availability	Discontinued
Generic	Valdecoxib
Valdecoxib Other Names	Valdecoxib
Related Drugs	Humira, Buprenex, aspirin, prednisone, ibuprofen, acetaminophen, tramadol, meloxicam, naproxen, diclofenac
Type	Tablet
Formula	C₁₆H₁₄N₂O₃S
Weight	Average: 314.359 Monoisotopic: 314.072513014
Protein binding	98%
Groups	Approved, Investigational, Withdrawn
Therapeutic Class
Manufacturer	Comed Chemicals Pvt Ltd
Available Country	India
Last Updated:	September 19, 2023 at 7:00 am

Uses

Leap is a COX-2 inhibitor used to treat osteoarthritis and dysmenorrhoea.

For the treatment of osteoarthritis and dysmenorrhoea

Leap is also used to associated treatment for these conditions: Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis

How Leap works

Both COX-1 and COX-2 catalyze the conversion of arachidonic acid to prostaglandin (PG) H2, the precursor of PGs and thromboxane. Leap selectively inhibits the cyclooxygenase-2 (COX-2) enzyme, important for the mediation of inflammation and pain. Unlike non-selective NSAIDs, valdecoxib does not inhibit platelet aggregation.

Toxicity

Symptoms following acute NSAID overdoses are usually limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Hypertension, acute renal failure, respiratory depression and coma may occur, but are rare.

Food Interaction

Avoid alcohol. Ingesting alcohol may increase the risk of gastrointestinal bleeding.
Take with or without food.

Leap Drug Interaction

Moderate: amikacin, candesartan / hydrochlorothiazide, entecavir, carbamazepine, desogestrel / ethinyl estradiolUnknown: amphotericin b lipid complex, albumin human, zolpidem, ipratropium, amoxicillin / clavulanate, calcium / vitamin d, calcium carbonate, Allergy , albuterol / ipratropium, rosuvastatin, glucose, acetaminophen / phenyltoloxamine, esomeprazole, acetaminophen, acetaminophen

Volume of Distribution

86 L

Elimination Route

Oral bioavailability is 83%.

Half Life

8-11 hours

Clearance

oral cl=6 L/h
6 – 7 L/h [In patients undergoing hemodialysis]
6 – 7 L/h [healthy elderly subjects]

Elimination Route

Leap is eliminated predominantly via hepatic metabolism with less than 5% of the dose excreted unchanged in the urine and feces. About 70% of the dose is excreted in the urine as metabolites, and about 20% as valdecoxib N-glucuronide.